Adial Pharmaceuticals
ADIL
26 hedge funds and large institutions have $2.27M invested in Adial Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 4 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
13% more funds holding
Funds holding: 23 → 26 (+3)
0.01% less ownership
Funds ownership: 0.02% → 0.01% (-0.01%)
64% less capital invested
Capital invested by funds: $6.38M → $2.27M (-$4.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$216K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$118K |
| 3 |
Millennium Management
New York
|
+$57K |
| 4 |
Truist Financial
Charlotte,
North Carolina
|
+$48.9K |
| 5 |
VF
Virtu Financial
New York
|
+$46.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$3.65M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
-$63K |
| 3 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
-$19K |
| 4 |
EWM
Empirical Wealth Management
Seattle,
Washington
|
-$14.5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$14K |
ADIL Hedge Fund Activity: Q2 2022 in Review
26 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Adial Pharmaceuticals (ADIL) for Q2 2022, worth a combined $2.27M — down 64% from $6.38M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new ADIL positions and 4 closed out — a net gain of 3 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $216K. The largest seller was Armistice Capital, exiting entirely with an estimated $3.65M sold.
- 26 institutional investors held Adial Pharmaceuticals (ADIL) as of Q2 2022, up from 23 in Q1 2022.
- Funds reported $2.27M of Adial Pharmaceuticals stock for Q2 2022, down 64% quarter-over-quarter.
- 7 funds opened new Adial Pharmaceuticals positions in Q2 2022 and 4 closed out, a net change of +3 holders.
- The largest Adial Pharmaceuticals buyer in Q2 2022 was Renaissance Technologies, an estimated $216K added.
- The largest Adial Pharmaceuticals seller in Q2 2022 was Armistice Capital, an estimated $3.65M sold.
Based on aggregated 13F filings for Q2 2022.